129 related articles for article (PubMed ID: 38467640)
21. Interleukin 1/Toll-like receptor-induced autophosphorylation activates interleukin 1 receptor-associated kinase 4 and controls cytokine induction in a cell type-specific manner.
Cushing L; Stochaj W; Siegel M; Czerwinski R; Dower K; Wright Q; Hirschfield M; Casanova JL; Picard C; Puel A; Lin LL; Rao VR
J Biol Chem; 2014 Apr; 289(15):10865-10875. PubMed ID: 24567333
[TBL] [Abstract][Full Text] [Related]
22. Design of Novel IRAK4 Inhibitors Using Molecular Docking, Dynamics Simulation and 3D-QSAR Studies.
Bhujbal SP; He W; Hah JM
Molecules; 2022 Sep; 27(19):. PubMed ID: 36234844
[TBL] [Abstract][Full Text] [Related]
23. IRAK4 in TLR/IL-1R signaling: possible clinical applications.
Li X
Eur J Immunol; 2008 Mar; 38(3):614-8. PubMed ID: 18286571
[TBL] [Abstract][Full Text] [Related]
24. Mechanism of dysfunction of human variants of the IRAK4 kinase and a role for its kinase activity in interleukin-1 receptor signaling.
De S; Karim F; Kiessu E; Cushing L; Lin LL; Ghandil P; Hoarau C; Casanova JL; Puel A; Rao VR
J Biol Chem; 2018 Sep; 293(39):15208-15220. PubMed ID: 30115681
[TBL] [Abstract][Full Text] [Related]
25. Small Molecule Inhibition of Interleukin-1 Receptor-Associated Kinase 4 (IRAK4).
Genung NE; Guckian KM
Prog Med Chem; 2017; 56():117-163. PubMed ID: 28314411
[TBL] [Abstract][Full Text] [Related]
26. Recent advances in the discovery of small molecule inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4) as a therapeutic target for inflammation and oncology disorders.
Chaudhary D; Robinson S; Romero DL
J Med Chem; 2015 Jan; 58(1):96-110. PubMed ID: 25479567
[TBL] [Abstract][Full Text] [Related]
27. Clinical IRAK4 deficiency caused by homozygosity for the novel
Jia A; James E; Lu HY; Sharma M; Modi BP; Biggs CM; Hildebrand KJ; Chomyn A; Erdle S; Kular H; Turvey SE
Cold Spring Harb Mol Case Stud; 2020 Jun; 6(3):. PubMed ID: 32532880
[TBL] [Abstract][Full Text] [Related]
28. IRAK4 kinase activity is not required for induction of endotoxin tolerance but contributes to TLR2-mediated tolerance.
Xiong Y; Pennini M; Vogel SN; Medvedev AE
J Leukoc Biol; 2013 Aug; 94(2):291-300. PubMed ID: 23695305
[TBL] [Abstract][Full Text] [Related]
29. Discovery of novel 2-anilinopyrazolo[1,5-a]pyrimidine derivatives as c-Src kinase inhibitors for the treatment of acute ischemic stroke.
Mukaiyama H; Nishimura T; Shiohara H; Kobayashi S; Komatsu Y; Kikuchi S; Tsuji E; Kamada N; Ohnota H; Kusama H
Chem Pharm Bull (Tokyo); 2007 Jun; 55(6):881-9. PubMed ID: 17541186
[TBL] [Abstract][Full Text] [Related]
30. A critical role for IRAK4 kinase activity in Toll-like receptor-mediated innate immunity.
Kim TW; Staschke K; Bulek K; Yao J; Peters K; Oh KH; Vandenburg Y; Xiao H; Qian W; Hamilton T; Min B; Sen G; Gilmour R; Li X
J Exp Med; 2007 May; 204(5):1025-36. PubMed ID: 17470642
[TBL] [Abstract][Full Text] [Related]
31. Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).
Seganish WM
Expert Opin Ther Pat; 2016 Aug; 26(8):917-32. PubMed ID: 27310003
[TBL] [Abstract][Full Text] [Related]
32. Establishing and Validating Cellular Functional Target Engagement Assay for Selective IRAK4 Inhibitor Discovery.
Chen Y; Sun D; Yang R; Lim J; Sondey C; Presland J; Rakhilina L; Addona G; Kariv I; Chen H
SLAS Discov; 2021 Sep; 26(8):1040-1054. PubMed ID: 34130529
[TBL] [Abstract][Full Text] [Related]
33. Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor.
Henderson JL; Kormos BL; Hayward MM; Coffman KJ; Jasti J; Kurumbail RG; Wager TT; Verhoest PR; Noell GS; Chen Y; Needle E; Berger Z; Steyn SJ; Houle C; Hirst WD; Galatsis P
J Med Chem; 2015 Jan; 58(1):419-32. PubMed ID: 25353650
[TBL] [Abstract][Full Text] [Related]
34. Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy.
Kelly PN; Romero DL; Yang Y; Shaffer AL; Chaudhary D; Robinson S; Miao W; Rui L; Westlin WF; Kapeller R; Staudt LM
J Exp Med; 2015 Dec; 212(13):2189-201. PubMed ID: 26621451
[TBL] [Abstract][Full Text] [Related]
35. The kinase IRAK4 promotes endosomal TLR and immune complex signaling in B cells and plasmacytoid dendritic cells.
Corzo CA; Varfolomeev E; Setiadi AF; Francis R; Klabunde S; Senger K; Sujatha-Bhaskar S; Drobnick J; Do S; Suto E; Huang Z; Eastham-Anderson J; Katewa A; Pang J; Domeyer M; Dela Cruz C; Paler-Martinez A; Lau VWC; Hadadianpour A; Ramirez-Carrozi V; Sun Y; Bao K; Xu D; Hunley E; Brightbill HD; Warming S; Roose-Girma M; Wong A; Tam L; Emson CL; Crawford JJ; Young WB; Pappu R; McKenzie BS; Asghari V; Vucic D; Hackney JA; Austin CD; Lee WP; Lekkerkerker A; Ghilardi N; Bryan MC; Kiefer JR; Townsend MJ; Zarrin AA
Sci Signal; 2020 Jun; 13(634):. PubMed ID: 32487715
[TBL] [Abstract][Full Text] [Related]
36. IRAK4 inhibition dampens pathogenic processes driving inflammatory skin diseases.
Lavazais S; Jargosch M; Dupont S; Labéguère F; Menet C; Jagerschmidt C; Ohm F; Kupcsik L; Parent I; Cottereaux C; Marsais F; Oste L; Van de Water A; Christophe T; De Vos S; Fallon P; Lauffer F; Clément-Lacroix P; Eyerich K; Brys R
Sci Transl Med; 2023 Feb; 15(683):eabj3289. PubMed ID: 36791209
[TBL] [Abstract][Full Text] [Related]
37. A small molecule potent IRAK4 inhibitor abrogates lipopolysaccharide-induced macrophage inflammation in-vitro and in-vivo.
Choudhary SA; Patra D; Sinha A; Mazumder S; Pant R; Chouhan R; Jha AN; Prusty BM; Manna D; Das SK; Tikoo K; Pal D; Dasgupta S
Eur J Pharmacol; 2023 Apr; 944():175593. PubMed ID: 36804543
[TBL] [Abstract][Full Text] [Related]
38. Targeted Nanocarriers for Systemic Delivery of IRAK4 Inhibitors to Inflamed Tissues.
Park Y; Korzun T; Moses AS; Singh P; Levasseur PR; Demessie AA; Sharma KS; Morgan T; Raitmayr CJ; Avila U; Sabei FY; Taratula OR; Marks DL; Taratula O
Small; 2024 Jan; 20(4):e2306270. PubMed ID: 37702136
[TBL] [Abstract][Full Text] [Related]
39. Efforts towards the optimization of a bi-aryl class of potent IRAK4 inhibitors.
Hanisak J; Seganish WM; McElroy WT; Tang H; Zhang R; Tsui HC; Fischmann T; Tulshian D; Tata J; Sondey C; Devito K; Fossetta J; Garlisi CG; Lundell D; Niu X
Bioorg Med Chem Lett; 2016 Sep; 26(17):4250-5. PubMed ID: 27476420
[TBL] [Abstract][Full Text] [Related]
40. Potent and Selective Amidopyrazole Inhibitors of IRAK4 That Are Efficacious in a Rodent Model of Inflammation.
McElroy WT; Tan Z; Ho G; Paliwal S; Li G; Seganish WM; Tulshian D; Tata J; Fischmann TO; Sondey C; Bian H; Bober L; Jackson J; Garlisi CG; Devito K; Fossetta J; Lundell D; Niu X
ACS Med Chem Lett; 2015 Jun; 6(6):677-82. PubMed ID: 26101573
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
